Background: Depressive symptoms occur in several psychiatric disorders, often in the absence of a formal diagnosis of depression. We aimed to evaluate the efficacy and the tolerability of amisulpride, both alone and as augmentation therapy, in the treatment of depressive symptoms in individuals with any major psychiatric disorder.
Methods: We searched PubMed, Embase, PsycINFO, GreyLit, OpenGrey and ProQuest up to March 2020 for randomised controlled trials focussing on the treatment of an acute depressive episode in any major psychiatric disorder. A random-effect meta-analysis was performed to synthesize the findings on depressive symptoms (primary outcome), response rate and tolerability.
Results: We retrieved 11 studies including 2065 patients with a diagnosis of dysthymia (eight studies), major depression (one study) or schizophrenia (two studies). Amisulpride 50 mg/day was associated with a larger reduction of depressive symptoms compared to placebo (standardised mean difference [SMD] = -0.70, CI 95% -0.92, -0.49; I = 0.0%), and was found to be comparable to selective serotonin reuptake inhibitors (SSRIs; SMD = -0.08, CI 95% -0.23, 0.06, I = 0.0%), amineptine, imipramine and amitriptyline in the treatment of dysthymia (three studies, not pooled). In individuals with schizophrenia, amisulpride administered at higher doses (>400 mg/day) was comparable to olanzapine and risperidone (two studies, not pooled). In terms of tolerability, amisulpride was superior to placebo for dysthymia (odds ratio [OR] = 3.94, CI 95% 1.07, 14.48; I = 0.0) and comparable with SSRIs (OR = 0.94, CI 95% 0.55, 1.62; I = 0.0%).
Conclusion: Treatment with amisulpride could be a valid choice for selected individuals with dysthymia or depressive symptoms in the context of schizophrenia. More studies on the efficacy and tolerability of amisulpride are needed to draw firm conclusions on its potential benefits in other psychiatric disorders.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596405 | PMC |
| http://dx.doi.org/10.1002/hup.2801 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dopamine genetic risk scores and psychiatric symptoms: Interacting risk factors for impulse control behaviours in de novo Parkinson's disease.
J Neuropsychol
January 2025
Department of Health, Medical and Neuropsychology, Leiden University, Leiden, The Netherlands.
Up to 45% of patients with Parkinson's disease (PD) experience impulse control disorders (ICDs), characterized by a loss of voluntary control over impulses, drives or temptations. This study aimed to investigate whether previously identified genetic and psychiatric risk factors interact towards the development of ICDs in PD. A total of 278 de novo PD patients (ICD-free at enrollment) were selected from the Parkinson's Progression Markers Initiative database.
View Article and Find Full Text PDFCultural differences in diagnosis and treatment perceptions: Turkish collectivistic representations of common mental disorders.
Int J Qual Stud Health Well-being
December 2025
Department of Language and Communication, Centre for Language Studies, Radboud University, Nijmegen, The Netherlands.
Purpose: Attention-deficit/hyperactivity disorder (ADHD) is less diagnosed among Turkish children, and Turkish clients drop out more often from depression treatments than Dutch clients. This article proposes that cultural differences in collectivistic versus individualistic perceptions of getting an ADHD diagnosis and being treated for depression might explain these ethnic disparities, which have been explored in this study.
Methods: Nine focus group discussions with Turkish individuals and 18 interviews with primary mental health practitioners were conducted.
Background: COVID-19 is a transmissible and infectious disease with symptoms similar to pneumonia, ranging from moderate to severe. This study investigated the psychological experiences of patients both during their illness and after their recovery.
Methods: The study employed purposive sampling and semi-structured interviews to gather insights from 13 COVID-19 survivors (7 women and 6 men).
Self-administered active versus sham acupressure for diarrhea predominant irritable bowel syndrome: a nurse-led randomized clinical trial.
BMC Nurs
January 2025
Medical Surgical Nursing Department, Faculty of Nursing, Alexandria University, Alexandria, Egypt.
Background: Diarrhea-predominant irritable bowel syndrome (IBS-D) significantly impacts patients' quality of life, with existing treatments offering limited relief. Self-administered acupressure presents a potential non-invasive, cost-effective treatment option that could alleviate symptoms and enhance health outcomes in these patients.
Aim: This randomized controlled trial aimed to evaluate the effect of active acupressure compared to sham acupressure on primary and secondary outcomes among IBS-D patients.
Help-seeking for depression among Vietnamese migrant workers in Japan and factors related to their intentions to seek help from a psychiatrist: a cross-sectional study.
BMC Public Health
January 2025
Center for Basic Medical Research, International University of Health and Welfare, 2600-1 Kitakanemaru, Ohtawara-City, Tochigi, 324-8501, Japan.
Background: Foreign workers are at risk for depression, and Vietnamese people tend to be reluctant to seek professional mental health care. Although Vietnamese people are the largest population among foreign workers in Japan, evidence concerning their help-seeking experiences and strategies to promote help-seeking in this population is lacking. This study aimed to identify the percentage of Vietnamese migrant workers in Japan who have sought help from healthcare professionals for depressive symptoms and to explore the factors related to their intentions to seek help from a psychiatrist.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!